PMI Italy Launches IQOS iluma i Prime Heating Tobacco Device

Oct.11.2024
PMI Italy Launches IQOS iluma i Prime Heating Tobacco Device
PMI's Italian subsidiary launches "IQOS iluma i Prime", marking a decade of innovative tobacco products and global expansion.

According to a report by Zazoom on October 10th, Philip Morris International's Italian subsidiary announced the launch of the heated tobacco device "IQOS iluma i Prime". The company emphasized that it has invested over $12.5 billion in the development, scientific validation, production, marketing and continuous innovation of its new tobacco products, which are currently sold in over 90 markets worldwide.


The company's head of new tobacco product category, Gianluca Iannelli, stated that...


We hope to achieve a transformative milestone in our business, and this approach is bearing fruit: in Italy, over two million smokers have switched to our smokeless products and abandoned cigarettes.


The company stated that the launch of "IQOS iluma i Prime" comes on the occasion of the 10th anniversary of the first release of IQOS. IQOS was first launched globally in Italy and Japan in 2014.


PMI plays a significant role in the industrial chain in Italy, having invested over 2.5 billion euros in tobacco cultivation over the past 20 years. Additionally, PMI has invested 1.5 billion euros in production facilities in the Crexienza region, with products being exported to 40 countries.


PMI Italy celebrates the 10th anniversary of its production site, having collaborated with approximately 1,000 supply and service companies in Italy so far. The company aims to continue driving the transformation of new tobacco products and promises to develop its business in a sustainable and responsible manner.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Kentucky to issue provisional state licenses to tobacco, nicotine and vapor retailers who applied before Jan. 1, 2026
Kentucky to issue provisional state licenses to tobacco, nicotine and vapor retailers who applied before Jan. 1, 2026
Kentucky will issue provisional state licenses to tobacco, nicotine and vapor product retailers that applied for a license with the Department of Alcoholic Beverage Control (ABC) before Jan. 1, 2026.
Dec.31 by 2FIRSTS.ai
Belgium: BAT plans to cut 51 jobs at Groot-Bijgaarden site
Belgium: BAT plans to cut 51 jobs at Groot-Bijgaarden site
British American Tobacco (BAT) has announced plans to cut 51 jobs at its Groot-Bijgaarden facility in Belgium, disclosed during a special works council meeting.
Jan.15 by 2FIRSTS.ai
EVO NXT 2026 Offers Unique Insights Into A Dynamic Industry
EVO NXT 2026 Offers Unique Insights Into A Dynamic Industry
Feb.09
Scientific talk in Bursa Nilüfer spotlights cigarette and e-cigarette addiction and youth risks
Scientific talk in Bursa Nilüfer spotlights cigarette and e-cigarette addiction and youth risks
Nilüfer Municipality in Bursa held a scientific talk titled “Does Addiction Change Form? Cigarettes, E-Cigarettes and Lung Health” as part of February 9 Quit Smoking Day, aiming to raise awareness of the social impact of tobacco addiction. Experts discussed cigarette and e-cigarette addiction, risks for young people, harms of secondhand smoke for children, and health outcomes linked to tobacco use.
Feb.10 by 2FIRSTS.ai
Japan Tobacco expands Ploom EVO stick lineup, rolling out four new variants in Japan in two phases
Japan Tobacco expands Ploom EVO stick lineup, rolling out four new variants in Japan in two phases
Japan Tobacco (JT) is adding four new EVO variants for its Ploom heated tobacco range—Green Mint, Cacao Mint Crystal, Tropical Lime Crystal and Sakura Regular—set to launch in two waves on Jan. 22 and Feb. 3. The initial release will be via the CLUB JT online store and Ploom retail stores.
Jan.23 by 2FIRSTS.ai
FDA Details Carcinogenicity Tiering and ELCR Framework as Small Manufacturers Press for Predictability
FDA Details Carcinogenicity Tiering and ELCR Framework as Small Manufacturers Press for Predictability
During the “Toxicological Profile” session at FDA’s Feb 10 PMTA roundtable, officials outlined the carcinogenicity tiering system and Excess Lifetime Cancer Risk (ELCR) framework used in ENDS reviews under the APPH standard. Small manufacturers questioned database transparency, exposure assumptions, and the existence of clear compliance benchmarks. FDA reiterated toxicological risk is assessed case by case within a broader population-level determination.
Feb.11